ResMed stock: Morgan Stanley raises target for ResMed stock to USD 233.00

Published on 10/24/2026 at 00:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Morgan Stanley raised its target to USD 233.00 on October 22, 2026. For ResMed stock, results arrive October 29 after USD 5.65 billion revenue.

Analyst view and company dates

Morgan Stanley raised its ResMed target to USD 233.00 on October 22, 2026.
Fiscal 2026 revenue reached USD 5.65 billion, up 10.00 percent from fiscal 2025.
ResMed plans to report first-quarter fiscal 2027 results on October 29, 2026.

Trading-Floor mit großen Bildschirmen und Kursdiagrammen sowie diskutierenden Händlern — ResMed Inc. (ISIN US7611521078): Börsen-Editorialfoto zeigt einen belebten Trading-Floor mit Medizintechnik-Aktiencharts auf großen Bildschirmen, Illustration mit AI erstellt.

ResMed (ISIN US7611521078) drew a fresh analyst target of USD 233.00 from Morgan Stanley on October 22, 2026, according to Moomoo. The company is scheduled to publish first-quarter fiscal 2027 results on October 29, 2026, after the New York Stock Exchange closes, as ResMed announced on October 1, 2026.

Three events shape the setup

On August 6, 2026, ResMed reported quarterly revenue of USD 1.46 billion and adjusted earnings per share of USD 2.95, versus consensus of USD 2.89, according to MarketBeat.

On September 15, 2026, RBC raised its target from USD 244.00 to USD 262.00, while retaining an outperform rating, according to MarketBeat.

On October 22, 2026, Morgan Stanley raised its target to USD 233.00, making the latest analyst action the key near-term valuation reference, as Moomoo reported.

What does the target mean for valuation?

ResMed's last NYSE price was USD 252.86 on October 23, 2026 at 4:00 p.m. ET. The Morgan Stanley target therefore stood 7.85 percent below that price, while the latest quarterly result showed revenue growth of 8.60 percent from the prior-year quarter. The contrast leaves the October 29 report as the next concrete test for the valuation.

Dates investors can track

The next reporting date is October 29, 2026, when ResMed plans to release first-quarter fiscal 2027 results after the NYSE close, according to ResMed. The next annual meeting is scheduled for November 18, 2026, according to the company's proxy statement dated October 1, 2026, which also sets out the fiscal 2026 performance figures and governance agenda.

Revenue provides the operating baseline

Fiscal 2026 revenue reached USD 5.65 billion, up 10.00 percent from USD 5.15 billion in fiscal 2025. GAAP net income rose to USD 1.52 billion from USD 1.40 billion, while operating cash flow reached USD 1.81 billion. The figures come from the fiscal 2026 financial statements and the proxy materials filed by ResMed. This combination of revenue growth and cash generation gives the upcoming quarter a clear operating benchmark.

NYSE price and analyst target

ResMed was last at USD 252.86 on the NYSE on October 23, 2026 at 4:00 p.m. ET. The share's 52-week range was USD 180.27 to USD 277.67 on that date, placing the last price 8.94 percent below the high. The further course of trading is shown by the continuously updated real-time quote of ResMed stock.